ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ('ESSA,' or the 'Company') (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025.
'We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value,' said David Parkinson, MD, President and CEO of ESSA. 'We have taken productive steps towards a decision and hope to share an update in the near future.'
Second Quarter 2025 and Recent Updates
Summary of Financial Results
(Amounts expressed in U.S. dollars)
Liquidity and Outstanding Share Capital
About ESSA Pharma Inc.
ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
Forward-Looking Statement Disclaimer
This release contains certain information which, as presented, constitutes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and 'forward-looking information' within the meaning of applicable Canadian securities laws (collectively, 'forward-looking statements'). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as 'anticipate', 'believe', 'plan', 'estimate', 'expect', and 'intend', statements that an action or event 'may', 'might', 'could', 'should', or 'will' be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the termination of the Company's clinical studies of masofaniten, the Company's evaluation of its strategic alternatives and future announcements in connection therewith and the Company's expected headcount and cost reductions.
Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) obtaining necessary regulatory approvals; (iii) ESSA's ability to efficiently wind down its clinical trial activities (iv) that one or more strategic options may be available to ESSA at reasonably acceptable terms; and (v) general business, market and economic conditions.
Forward-looking statements are developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 10-K dated December 17, 2024, under the heading 'Risk Factors', a copy of which is available on ESSA's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca, and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.
Contacts
ESSA Pharma Inc.
David Wood, Chief Financial Officer
778.331.0962
[email protected]
Investors and Media
Argot Partners
212.600.1902
[email protected]
ESSA PHARMA INC.
CONSOLIDATED BALANCE SHEETS
Unaudited
Amounts in thousands of United States dollars
ESSA PHARMA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Unaudited
Amounts in thousands of United States dollars, except share and per share data
View original content: https://www.prnewswire.com/news-releases/essa-pharma-reports-financial-results-for-fiscal-second-quarter-ended-march-31-2025-302449410.html
SOURCE ESSA Pharma Inc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
More Americans are driving to Canada than Canadians to the U.S., report finds
More American travellers drove to Canada in July than Canadians did to the United States, according to a new report by Statistics Canada. This is the first time such a reversal has taken place since before the COVID-19 pandemic. The dramatic decline of Canadians travelling to the U.S. was sparked last year, with U.S. President Donald Trump's heated rhetoric about Canada becoming the 51st state that led to an ongoing trade war and lingering tension between the two countries. The data for last month shows that 1.8 million American residents drove to Canada, compared to the 1.7 million Canadian residents who made a return trip from the U.S. by car. Canadian road trips to U.S. plunge for seventh month as boycott continues Both countries saw a decline at land border crossings last month. For Americans driving to Canada, there was a slight dip of 7.4 per cent compared to the same month last year. It was also the sixth consecutive month of year-over-year declines. However, the decline was much steeper for Canadians returning from the U.S. this July compared to the previous year, at nearly 37 per cent. Last month marked the seventh consecutive month of year-over-year declines, StatCan said. 'In 2024, Canadian-resident trips to the United States totalled 39 million, representing 75 per cent of all Canadian-resident travel abroad,' according to another StatCan report published earlier this summer about travel to the U.S. 'However, recent data on foreign travel suggest that Canadians' travel sentiment toward their southern neighbour has been shifting in early 2025.' Although the data reflects a 'notable change in travel patterns,' StatCan said it is 'unclear whether the change is temporary or part of a more permanent shift.' As for air travel, the number of non-resident visitors who flew to Canada increased in July. There were 1.4 million of them — up by just over 3 per cent since the same time last year. While the bump was largely due to residents who came from overseas (up 5.6 per cent this year), American travellers were also up by just under 1 per cent. The highest number of U.S.-resident arrivals by air was 31,600 Americans on July 3, before the Independence Day long weekend in the U.S. Meanwhile, the number of Canadians returning home from abroad by air last month was down by 5.3 per cent compared to the previous year. In particular, Canadians flying back from the U.S. also decreased by nearly 26 per cent since the same time last year. Canadian permanent residents will now have to pay 'visa integrity fee' to enter U.S. Here's what it is An American sent to Canada was shocked by how furious Canadians are at the U.S. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
Yahoo
7 minutes ago
- Yahoo
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
